Glioma progression evaluation
From 01-09-2012 to 31-08-2013
Description
Due to recent changes in glioma treatment, e.g. combined radiotherapy with temozolomide(RT/CT), and anti-angiogenic therapy (AAT), the traditional Macdonald criteria for tumor response evaluationare increasingly recognized to be not adequate any more, since effects of pseudo-progression and pseudoresponseare not covered by these criteria. In order to overcome these problems, the R esponse A ssessment inN euro-O ncology (RANO) Working Group is an international effort to develop new standardized responsecriteria for malignant glioma, but according to their recent 2010 paper with updated response criteria, should tobe regarded as ”a work-in-progress”, rather than definitive criteria. Since the formulation of the Macdonaldcriteria in the beginning of the nineties, many novel MR-techniques have become available, now widely used inclinical routine, that allow for the non-invasive retrieval of morphological, functional and metabolic propertiesof brain tumors. In the same 2010 paper of the RANO group, it was pointed out that there is an urgent need toinvestigate whether these contemporary state-of-the-art MR-techniques (i.e. diffusion weighted imaging,dynamic susceptibility contrast enhanced perfusion, imaging, MR-spectroscopy (MRS)) are able to fill the gapin the proper evaluation of tumor progression. The underlying neuroradiological study should be regerded as astructured systematic multimodal attempt to implement these state-of-the-art MR-techniques as indicated in the2010 RANO paper.
Team
- Sabine Van Huffel, Co-promoter
- Johannes Slotboom, Promoter (External)
Financing
Funding: OTHER - Other Funding Agencies
Program/Grant Type: Other - Other
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.